Primary Total: $52,502,661
Total: $42,538,086
Primary Total: $39,077,134
Total: $2,563,551
Primary Total: $2,037,955
93-LEUK-08: Treatment of Previously Untreated Patients with Chronic Lymphocytic Leukemia with Leustatin (2-Chlorodeoxyad enosine), (427996), Ortho Biotech Inc, $10,000 (adjustment).
*Planning Grants for Prospective Cancer Centers, (433334), Natl Cancer Institute, $51,450.
*Planning Grants for Prospective Cancer Centers, (429225), Natl Cancer Institute, $257,250.
*Planning Grants for Prospective Cancer Centers, (433332), Natl Cancer Institute, $52,013.
*Planning Grants for Prospective Cancer Centers, (433333), Natl Cancer Institute, $76,528.
*Planning Grants for Prospective Cancer Centers, (433335), Natl Cancer Institute, $8,820.
Sister to Sister/Data Based Intervention, (429420), KY Cab for Human Resources, $25,860.
Patient Services Reporting System, (429419), KY Cab for Human Resources, $21,617.
Central Highlands Appalachian Leadership Initiative on Cancer (CHALIC) Restricted Funds Scope Account, (433521), Natl Cancer Institute, $16,443.
Cancer Information Service, (426943), Natl Cancer Institute, $778,388 (adjustment).
Central Highlands Appalachian Leadership Initiative on Cancer (CHALIC), (433349), Natl Cancer Institute, $24,500.
Central Highlands Appalachian Leadership Initiative on Cancer (CHALIC), (433354), Natl Cancer Institute, $59,373.
Central Highlands Appalachian Leadership Initiative on Cancer (CHALIC), (429460), Natl Cancer Institute, $323,798.
Sister to Sister, (428836), Natl Alliance of Breast Cancer Organizations, $10,000 (adjustment).
Kentucky Cancer Registry Program, (429520), Center for Disease Control, $270,485.
93-MISC-34: (MP # 39-92-P) A Pilot Study of the Safety and Efficacy of an Intralesionally Administered Cisplatin Therapeutic Implant (MP-5010) in Patients with Superficially Accesibly Tumors of Any Histology, (428032), Matrix Pharmaceutical Inc, $4,235 (adjustment).
*93-GI-20ZP: An Open, Randomized Multicenter Trial of TOMUDEX " (ZD 1694 Versus 5-Fluorouracil (5-FU) and Leucovorin (LV) in Patients with Advanced Colorectal Carcinoma, (427871), Alpha Therapeutic Co, $36,000 (adjustment).
*Antibody Mediated Delivery and Expression of Genes, (428868), Council for Tobacco Research, $89,347.
Regulation of Sicl Inhibition of Yeast Cdk Complexes, (428822), Natl Institute of General Medical Sciences, $190,515 (adjustment).
*Pre-Clinical Trail of CTB-1 )1F7) in SIV Infected Rhesus Macques, (428626), Immune Network Research Ltd, $45,571 (adjustment).
*NSABP - A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer, (426051), Univ of Pittsburgh, $71,316 (adjustment).
94-BRE-15SP: (Protocol #08341) A Phase III, Couble-Blind Randomized Study Evaluating the Safety and Efficacy of the Administration of SDZ ILS 969 [Recombinant Human Interleukim 6 (rhIL-6, E coli) Versus Placebo Following Cytoxan/, (428445), Sandoz Pharmaceuticals, $3,865 (adjustment).
NSABP Breast and Bowel Cancer Protocols C4249-182, (426515), Univ of Pittsburgh, $11,600 (adjustment).
*Cooperative Group for Breast and Colorectal Clinical Trials, (433369), Natl Cancer Institute, $4,995 (adjustment).
*Cooperative Group for Breast and Colorectal Clinical Trials, (429717), Natl Cancer Institute, $4,995 (adjustment).
*Immunotherapy and Gene Therapy of Cancer Program, (433093), Lucille P Markey Charitable Trust, $235,128 (adjustment).
*Immunotherapy and Gene Therapy of Cancer Program, (433066), Lucille P Markey Charitable Trust, $173,581 (adjustment).
For questions regarding listings, contact Ms. Deborah Davis, director of the Office of Sponsored Projects Administration, 214 Kinkead Hall, 0057, phone 257-8311. (ddavis@pop.uky.edu )
Last Updated: 6/30/03